One was the CAPSTONE-1 trial (8), which compared the efficacy and safety of the PD-L1 inhibitor adebrelimab (adebrelimab group) versus placebo in combination with chemotherapy (chemotherapy group) as first-line treatment in ES-SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.